Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
2.5
Journals
Applied Sciences
Special Issues
Medication-Related Osteonecrosis of the Jaw: Prevention, Diagnosis and Treatment
applsci-logo
Submit to Applied Sciences Review for Applied Sciences Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Medication-Related Osteonecrosis of the Jaw: Prevention, Diagnosis and Treatment

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Dentistry and Oral Sciences".

Deadline for manuscript submissions: closed (10 August 2022) | Viewed by 8681

Special Issue Editor

Prof. Dr. Sang Hwa Lee

E-Mail Website
Guest Editor
Div. of Oral and Maxillofacial Surgery Department of Dentistry, The Catholic University of Korea, Seoul 06591, Korea
Interests: oral surgery; MRONJ; dental treatment medically compromised patients; digital dentistry; big data analysis

Special Issue Information

Dear Colleagues,

Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction related with exposure to antiresorptive and antiangiogenic medication during the treatment of malignant and benign bone diseases such as osteoporosis, malignant bone metastases, multiple myeloma, and Paget’s disease. The involvement of various diseases and the multifactorial etiology of MRONJ reflect the fact that this disease requires the collaboration of various specialties.

This Special Issue of Applied Sciences, “Medication-Related Osteonecrosis of the Jaw: Prevention, Diagnosis and Treatment”, invites colleagues from all specialties related with MRONJ to present current research focusing on diagnosis, pathophysiology, and strategies for the management and prevention of MRONJ.

All article types are welcome, including clinical studies, reviews, big data analysis, and basic research.

Prof. Dr. Sang Hwa Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • medication related osteonecrosis of the jaw (MRONJ)
  • bisphosphonate
  • denosumab
  • anti-angiogenesis inhibitor
  • bone metastases
  • osteoporosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 257 KiB  
Article
What Do Prescribers of Bone Modifying Agents Know about Medication-Related Osteonecrosis of the Jaw? Is Current Prevention Enough?
by Mihai Vlad Golu, Ionela Pașcanu, Cornelia Togănel, Cecilia Petrovan, Adina Cosarcă, Despina Luciana Bereczki Temistocle and Alina Ormenișan
Appl. Sci. 2022, 12(18), 9224; https://doi.org/10.3390/app12189224 - 14 Sep 2022
Cited by 3 | Viewed by 1822
Abstract
Osteonecrosis of the jaw represents interference by external and internal factors in the natural bone remodeling system. Numerous bone remodeling agents (BMAs), such as bisphosphonates, denosumab, and tyrosine kinase inhibitors, can lead to medication-related osteonecrosis of the jaw (MRONJ). This is a serious [...] Read more.
Osteonecrosis of the jaw represents interference by external and internal factors in the natural bone remodeling system. Numerous bone remodeling agents (BMAs), such as bisphosphonates, denosumab, and tyrosine kinase inhibitors, can lead to medication-related osteonecrosis of the jaw (MRONJ). This is a serious condition that ocurs as a side-effect of treatment in patients with osteoporosis or malignancies. Antiresorptive drugs are medications that target osteoclasts with the aim of preventing bone resorption and are used to treat osteoporosis, osteopenia, and a variety of other conditions, such as Paget’s disease. They are also used in cancer patients with active bone metastases where antiresorptive treatment is used for the prevention of skeletal complications. Poor dental health, infections, and especially dental surgery are the primary causes of MRONJ, while other risk factors, such as smoking, alcohol abuse, and diabetes mellitus, can also influence its development. Prevention is the key component of management, and thus awareness of the risk factors among prescribers is very important. The aim of our study was to evaluate current knowledge about MRONJ among BMA prescribers in an academic hospital and their awareness about oral health and dental check-ups. By using a custom-designed questionnaire addressed to general and internal medical practitioners, endocrinologists, rheumatologists, and oncologists as an instrument for collecting data, we tried to identify trends in BMA prescription among different specialists and their recommended preventative measures, with the aim of creating new strategies to prevent the occurrence of MRONJ. The survey revealed a low awareness among physicians of the potential risk factors and underlined the need for a concerted effort to improve patient management. In this sense, a multidisciplinary team approach that includes the patient, the drug prescriber, the dentist, and the oral surgeon could significantly improve the quality of life of patients with MRONJ. Full article
(This article belongs to the Special Issue Medication-Related Osteonecrosis of the Jaw: Prevention, Diagnosis and Treatment)
7 pages, 4475 KiB  
Communication
Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw
by Sandra Bacián Martínez, Carlos Navarro Cuéllar, Carlos Navarro Vila, Edurne Palacios Weiss, Roser Pujol Romanyá, Álvaro del Amo Fernández de Velasco, Margarita Escrig de Teijeiro, José Luis del Castillo Pardo de Vera, Irene Rodríguez Pérez, Arturo Sánchez-Pérez, José J. Zamorano-León, Antonio López-Farré, María Isabel García-Hidalgo Alonso and Ignacio Navarro Cuéllar
Appl. Sci. 2021, 11(16), 7646; https://doi.org/10.3390/app11167646 - 20 Aug 2021
Viewed by 2629
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism of action is to prevent the activation [...] Read more.
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose mechanism of action is to prevent the activation of the RANK receptor on the surface of osteoclasts, has been associated with osteonecrosis of the jaw. Primary intraosseous squamous cell carcinoma (PIOSCC) is a rare neoplasm characterised by the presence of squamous cells within the maxillary or mandibular bone without an initial clinical association with the oral mucosa. We present a case of a PIOSCC in an osteonecrosis of the jaw related to a patient who received antiresorptive treatment with denosumab outlining the clinical and histopathological features of MRONJ and PIOSCC. Full article
(This article belongs to the Special Issue Medication-Related Osteonecrosis of the Jaw: Prevention, Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 286 KiB  
Review
Current Trends in Adjuvant Therapies for Medication-Related Osteonecrosis of the Jaw
by Gyu-Jo Shim, Joo-Young Ohe, Young-Jae Yoon, Yong-Dae Kwon and Deog-Yoon Kim
Appl. Sci. 2022, 12(8), 4035; https://doi.org/10.3390/app12084035 - 16 Apr 2022
Cited by 4 | Viewed by 3376
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a refractory disease, and a standard protocol for its treatment has not yet been established. In addition, owing to the old age of MRONJ patients and various complications, treatment goals focus on relieving the symptoms and [...] Read more.
Medication-related osteonecrosis of the jaw (MRONJ) is a refractory disease, and a standard protocol for its treatment has not yet been established. In addition, owing to the old age of MRONJ patients and various complications, treatment goals focus on relieving the symptoms and improving the quality of life. For this reason, different treatments such as conservative, surgical, and adjunctive treatments have been attempted. In particular, adjunctive treatment, which is effective for promoting healing and reducing recurrence, is gaining increasing interest, and several studies and clinical trials related to it have been published. Representative adjuvant therapies include teriparatide, recombinant human bone morphogenetic protein-2, hyperbaric oxygen, photobiomodulation and platelet concentrates. All have generally shown beneficial effects; however, no standard protocol for adjunctive treatment exists. Therefore, in this literature review, we briefly summarized the different adjuvant therapies and reviewed clinical reports to help decide whether to use adjuvant therapies in treating patients with MRONJ. Full article
(This article belongs to the Special Issue Medication-Related Osteonecrosis of the Jaw: Prevention, Diagnosis and Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop